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propriate (eg, those with a history of reproductive cancer
or demonstrated intolerance to HRT), and no publicly
subsidised therapeutic options are available in Australia
for such women. The aim of this study was to assess the
cost-effectiveness of raloxifene in preventing osteoporotic
fractures when HRT is inappropriate. METHODS: A
Markov model was developed to compare raloxifene with
no drug therapy in patients who are unable to use HRT.
Separate analyses were performed for those who are 
intolerant of HRT and those unsuitable for HRT due to
a history of reproductive cancer (with a consequent
greater baseline risk of breast cancer). Relative efﬁcacy
assumptions in the model were taken from randomised
controlled trials and the published literature. Primary out-
comes included vertebral fractures, non-vertebral frac-
tures and breast cancer in a cohort with a low bone
mineral density and an average age of 65 years. The
model ran for a period of 30 years, contained nine dis-
crete states and produced cost per quality-adjusted life-
year (QALY) values. Limited memory was incorporated
into the model by separating each fracture health state
into two states, representing a ﬁrst year and then subse-
quent years after fracture. RESULTS: The incremental
cost per QALY gained with raloxifene compared with no
therapy was $33,539 in those who are intolerant of HRT
and $29,780 per QALY in patients with a history of
reproductive cancer. Extensive sensitivity analyses 
indicated the results remained robust. CONCLUSIONS:
Raloxifene is a cost-effective therapy to reduce fracture
risk in postmenopausal women unsuitable for HRT.
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Continuity is a key treatment success factor to reduce
relapse and hospitalisation rates of schizophrenic
patients. Atypical antipsychotics with daily oral adminis-
tration are associated with improved efﬁcacy, tolerability
and compliance compared with older, conventional neu-
roleptics. Similarly, conventional depots have shown 
to reduce the risk of relapse over oral conventional. The
novel long-acting risperidone, administered intramuscu-
larly once every two weeks, is the ﬁrst long-acting for-
mulation of an atypical antipsychotic. OBJECTIVES: To
assess the cost-effectiveness of long-acting risperidone
versus oral olanzapine and haloperidol decanoate in
recently diagnosed schizophrenic patients. METHODS:
A cost-effectiveness analysis is considered. Main assump-
tion is that compliance improvement, thanks to a long-
acting formulation leads to an increased efﬁcacy. A
decision tree model was built with a time horizon of 
2 years. A French payers perspective was adopted.
Outcome probabilities and cost estimates were based on
published data, and supplemented with expert opinion.
Only direct medical costs were considered. Effectiveness
measures were relapse-free patients and patients main-
tained on the same treatment for 2 years. RESULTS:
76.30% of the patients receiving long-acting risperidone
remained relapse-free, compared with 69.60% with olan-
zapine and 47.70% with haloperidol decanoate. Of the
patients treated with long-acting risperidone, 82.7%
remained successfully on treatment for 2 years, compared
with 74.80% and 57.30% for patients treated with olan-
zapine and haloperidol decanoate respectively. Total
direct cost per patient over 2 years were €13,168 with
risperidone, €13,280 with olanzapine, and €16,910 with
haloperidol decanoate. Long-acting risperidone was the
dominant strategy in each case and remained dominant
strategy in sensitivity analyses. CONCLUSION: The
model indicates that treatment with long-acting risperi-
done reduces relapses, improves continuity of treatment,
and is associated with decreased total direct medical costs
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OBJECTIVE: To develop a health economic model for
estimating long-term costs and effects of treating chronic
venous leg ulcers (VLU) in Sweden on the basis of a 
randomised clinical trial (RCT) (UK-97-0005 Device +
Adaptic(R) (N:37) vs. Adaptic(R) only (N:36) under
Biﬂex(R) compression bandage). METHOD: Patient data
from a Swedish study including 252 VLU-patients
recruited from a specialised leg ulcer clinic in Malmö
between 1993 and 1997, is used in a Monte Carlo simu-
lation model to estimate individual ulcers’ time-to-healing
(TTH) with conventional treatment. In accordance with
patient data for 80 patients matching the inclusion crite-
ria in the UK-97-0005 Device RCT, we impose a lognor-
mal distribution on the TTH. The effect of UK-97-0005
Device is modeled as the relative efﬁcacy of UK-97-0005
Device versus placebo seen in the clinical trial at the end
of the 12 weeks study period (15%, p > 0.05). Costs are
evaluated from a health care provider perspective (mate-
